Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonmyeloablative Allogeneic HSCT in Pancreatic Cancer
NCT03236883Phase 1Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2016
- Primary completion
- Apr 2019
- Countries
- 1
01
Overview
Phase 1, open-label trial in pancreatic cancer (PC) (3 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Survival at 3 months. Status: unknown.
02
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03236883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03236883.